Literature DB >> 19416838

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Grazia Galli1, Kathy Hancock, Katja Hoschler, Joshua DeVos, Michaela Praus, Monia Bardelli, Carmine Malzone, Flora Castellino, Chiara Gentile, Teresa McNally, Giuseppe Del Giudice, Angelika Banzhoff, Volker Brauer, Emanuele Montomoli, Maria Zambon, Jacqueline Katz, Karl Nicholson, Iain Stephenson.   

Abstract

Proactive priming before the next pandemic could induce immune memory responses to novel influenza antigens. In an open-label study, we analyzed B cell memory and antibody responses of 54 adults who received 2 7.5-microg doses of MF59-adjuvanted A/Vietnam/1194/2004 clade 1 (H5N1) vaccine. Twenty-four subjects had been previously primed with MF59-adjuvanted or plain clade 0-like A/duck/Singapore/1997 (H5N3) vaccine during 1999-2001. The prevaccination frequency of circulating memory B cells reactive to A/Vietnam/1194/2004 was low in both primed and unprimed individuals. However, at day 21 after boosting, MF59-adjuvanted primed subjects displayed a higher frequency of H5N1-specific memory B cells than plain-primed or unprimed subjects. The immune memory was rapidly mobilized by a single vaccine administration and resulted in high titers of neutralizing antibodies to antigenically diverse clade 0, 1, and 2 H5N1 viruses already at day 7. In general, postvaccination antibody titers were significantly higher in primed subjects than in unprimed subjects. Subjects primed with MF59-adjuvanted vaccine responded significantly better than those primed with plain vaccine, most notably in early induction and duration of cross-reacting antibody responses. After 6 months, high titers of cross-reactive antibody remained detectable among MF59-primed subjects. We conclude that distant priming with clade 0-like H5N3 induces a pool of cross-reactive memory B cells that can be boosted rapidly years afterward by a mismatched MF59-adjuvanted vaccine to generate high titers of cross-reactive neutralizing antibodies rapidly. These results suggest that pre-pandemic vaccination strategies should be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416838      PMCID: PMC2674105          DOI: 10.1073/pnas.0903181106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Authors:  Iain Stephenson; Karl G Nicholson; Anthony Colegate; Audino Podda; John Wood; Ellen Ypma; Maria Zambon
Journal:  Vaccine       Date:  2003-04-02       Impact factor: 3.641

2.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Authors:  John J Treanor; James D Campbell; Kenneth M Zangwill; Thomas Rowe; Mark Wolff
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

3.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Authors:  Grazia Galli; Duccio Medini; Erica Borgogni; Luisanna Zedda; Monia Bardelli; Carmine Malzone; Sandra Nuti; Simona Tavarini; Chiara Sammicheli; Anne K Hilbert; Volker Brauer; Angelika Banzhoff; Rino Rappuoli; Giuseppe Del Giudice; Flora Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

4.  Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

Authors:  K Y Yuen; P K Chan; M Peiris; D N Tsang; T L Que; K F Shortridge; P T Cheung; W K To; E T Ho; R Sung; A F Cheng
Journal:  Lancet       Date:  1998-02-14       Impact factor: 79.321

5.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Authors:  Iain Stephenson; Roberto Bugarini; Karl G Nicholson; Audino Podda; John M Wood; Maria C Zambon; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

6.  Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Authors:  T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

Review 7.  Original antigenic sin. A confounding issue?

Authors:  L R Haaheim
Journal:  Dev Biol (Basel)       Date:  2003

8.  Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.

Authors:  Lance C Jennings; Arnold S Monto; Paul K S Chan; Thomas D Szucs; Karl G Nicholson
Journal:  Lancet Infect Dis       Date:  2008-10       Impact factor: 25.071

9.  Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

Authors:  I Stephenson; J M Wood; K G Nicholson; M C Zambon
Journal:  J Med Virol       Date:  2003-07       Impact factor: 2.327

10.  Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Authors:  Iain Stephenson; Maria C Zambon; Anna Rudin; Anthony Colegate; Audino Podda; Roberto Bugarini; Giusseppe Del Giudice; Ada Minutello; Susan Bonnington; Jan Holmgren; Kingston H G Mills; Karl G Nicholson
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

View more
  95 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.

Authors:  Ali H Ellebedy; Christopher Lupfer; Hazem E Ghoneim; Jennifer DeBeauchamp; Thirumala-Devi Kanneganti; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

3.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

Review 4.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

5.  Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.

Authors:  Mariette F Ducatez; Justin Bahl; Yolanda Griffin; Evelyn Stigger-Rosser; John Franks; Subrata Barman; Dhanasekaran Vijaykrishna; Ashley Webb; Yi Guan; Robert G Webster; Gavin J D Smith; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 6.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 7.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

Review 8.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

9.  Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.

Authors:  Nayer Khazeni; David W Hutton; Alan M Garber; Nathaniel Hupert; Douglas K Owens
Journal:  Ann Intern Med       Date:  2009-12-15       Impact factor: 25.391

10.  Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.

Authors:  Pio Lopez; Yolanda Caicedo; Alexandra Sierra; Sandrine Tilman; Ralf Clemens; Angelika Banzhoff
Journal:  Clin Vaccine Immunol       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.